Abstract PS5-07-19: ECOG-ACRIN tomosynthesis mammographic imaging screening trial (TMIST): Update for 2025
Abstract
The ECOG-ACRIN Tomosynthesis Mammographic Imaging Screening Trial is a clinical trial being conducted to determine if tomosynthesis (TM) should replace digital mammography (DM) for breast cancer screening based on the impact of the use of each technology on the number of advanced breast cancers in the population of women being screened over several years. If TM is better at finding the types of cancers that are most likely to lead to mortality, the population screened with TM would be expected to have fewer of these types of cancers over time compared with the population screened with DM. TMIST also includes secondary aims in the areas of imaging assessment, medical physics, breast biology and pathology, long-term follow-up, and health care utilization. Besides collection of demographic and clinical information, the study also has a collection of TM and DM screening mammograms, blood and buccal samples, and pathology diagnostic slides and tissue blocks.
Asymptomatic women ages 45 to 74 were enrolled into TMIST across 133 sites located in the United States, Canada, Argentina, Italy, Peru, Chile, South Korea, Spain, Taiwan, and Thailand. At the time of enrollment, women were randomized to undergo screening mammography with either TM or DM annually or biennially based on risk factors for their first 5 years on the study with up to 3 additional years of long-term follow-up under their routine breast screening protocols. Pathology materials for all enrolled women who undergo…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- Quantum Computing for Healthcare: A Review
- Automated in Silico Design of Homogeneous Catalysts
- Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
- In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.